おすすめの製品
グレード
pharmaceutical primary standard
APIファミリー
donepezil
メーカー／製品名
USP
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
InChI
1S/C24H29NO3.ClH/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18;/h3-7,14-15,17,20H,8-13,16H2,1-2H3;1H
InChI Key
XWAIAVWHZJNZQQ-UHFFFAOYSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
アプリケーション
- Novel tacrine-donepezil hybrids for Alzheimer′s treatment: Research has led to the development of new tacrine-donepezil hybrid compounds targeting Alzheimer′s disease, offering enhanced bioactivity and potential therapeutic benefits. These hybrids demonstrate multifunctional approaches in addressing neurodegenerative disorders by combining the acetylcholinesterase inhibitory effects of donepezil with the neuroprotective properties of tacrine (Bayraktar et al., 2024).
- Role of oligodendrocytes in Alzheimer′s disease: A study explores the involvement of oligodendrocytes in Alzheimer′s pathogenesis, highlighting potential mechanisms where donepezil could be implicated in modulating neurodegenerative processes. This research underscores the broader applicability of donepezil in understanding and potentially treating Alzheimer′s disease (Wang et al., 2024).
- Shenghui decoction′s neuroprotective effects: Investigating traditional therapies, this study assesses the neuroprotective effects of Shenghui decoction in an Alzheimer′s disease model. Donepezil′s role in this context is compared, contributing to broader insights into potential integrative treatments for neurodegenerative diseases (Lu et al., 2024).
- Electrochemical sensors for Alzheimer′s drug analysis: The development of electrochemical acetylcholinesterase sensors designed for the detection and study of anti-Alzheimer drugs like donepezil underscores its importance in research and therapeutic monitoring. This advancement supports the precise administration and study of donepezil in clinical settings (Ivanov et al., 2024).
- Modulating neurodegeneration with donepezil: A study on the combined effects of endothelin receptor agonist IRL-1620 with donepezil in an amyloid-β induced model of neurodegeneration in rats, expands our understanding of donepezil′s therapeutic potential beyond traditional applications, suggesting its utility in complex therapeutic regimes (Mahajan et al., 2024).
アナリシスノート
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
その他情報
Sales restrictions may apply.
関連製品
製品番号
詳細
価格
シグナルワード
Danger
危険有害性情報
危険有害性の分類
Acute Tox. 2 Oral - Eye Irrit. 2
保管分類コード
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
1224981-200MG:
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
この製品を見ている人はこちらもチェック
F M Garlich et al.
Clinical toxicology (Philadelphia, Pa.), 52(4), 291-294 (2014-04-17)
Donepezil is a centrally-acting, reversible acetylcholinesterase inhibitor that is used in the treatment of Alzheimer disease. Altered mental status, nausea, vomiting, and bradycardia have been reported in therapeutic and supratherapeutic ingestions of donepezil, though pediatric exposures have not been well-described.
Kenneth Rockwood et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 40(4), 564-571 (2013-06-22)
vascular dementia (VaD) and mixed Alzheimer's disease (AD/VaD) are common. How best to monitor treatment is not clear. Our objective was to compare responsiveness and construct validity of change scores, following donepezil treatment, of the standardized Mini-Mental State Examination (sMMSE)
Koteswara Rao Valasani et al.
Journal of chemical information and modeling, 53(8), 2033-2046 (2013-06-20)
Acetylcholinesterase (AChE) is a main drug target, and its inhibitors have demonstrated functionality in the symptomatic treatment of Alzheimer's disease (AD). In this study, a series of novel AChE inhibitors were designed and their inhibitory activity was evaluated with 2D
Hachiro Sugimoto et al.
Japanese journal of pharmacology, 89(1), 7-20 (2002-06-27)
A wide range of evidence shows that cholinesterase (ChE) inhibitors can interfere with the progression of Alzheimer's disease (AD). The earliest known ChE inhibitors, namely, physostigmine and tacrine, showed modest improvement in the cognitive function of AD patients. However, clinical
Jong-Il Kim et al.
International journal of pharmaceutics, 455(1-2), 31-39 (2013-08-13)
Although the taste-masking of bitter drug using ion exchange resin has been recognized, in vitro testing using an electronic tongue (e-Tongue) and in vivo bitterness test by human panel test was not fully understood. In case of orally disintegrating tablet
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）